AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16257877 — intervention group
Group type: COMPARATOR
Intervention: Non-stratified randomization
Number of subjects: 459
Study 16257877 — intervention group
Group type: COMPARATOR
Intervention: Stratified randomization
Number of subjects: 459
Study 11972576 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan orally disintegrating tablet 2.5 mg
Number of subjects: 471
Study 11972576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 471
Study 10102964 — intervention group
Group type: EXPERIMENTAL
Intervention: FCB group (furazolidone 100 mg b.d. and clarithromycin 250 mg b.d. with tripotassium dicitrato bismuthate 240 mg b.d.)
Number of subjects: 140
Study 10102964 — intervention group
Group type: EXPERIMENTAL
Intervention: FCL group (furazolidone 100 mg b.d. and clarithromycin 250 mg b.d. with lansoprazole 30 mg daily)
Number of subjects: 140
Study 10102964 — intervention group
Group type: EXPERIMENTAL
Intervention: FCO group (clarithromycin 250 mg b.d. and omeprazole 20 mg daily with furazolidone 100 mg b.d.)
Number of subjects: 140
Study 10102964 — intervention group
Group type: COMPARATOR
Intervention: MCO group (clarithromycin 250 mg b.d. and omeprazole 20 mg daily with metronidazole 400 mg b.d.)
Number of subjects: 140
Study 10102964 — intervention group
Group type: COMPARATOR
Intervention: MCO group (metronidazole-sensitive isolates)
Number of subjects: 140
Study 10102964 — intervention group
Group type: COMPARATOR
Intervention: MCO group (metronidazole-resistant strains)
Number of subjects: 140
Study 8547961 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tumor necrosis factor (TNF) and actinomycin D
Number of subjects: 0
Study 2180849 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg)
Number of subjects: 81
Study 2180849 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (12.5 mg)
Number of subjects: 81
Study 2180849 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril and Hydrochlorothiazide combination (32.5 mg)
Number of subjects: 81
Study 2180849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 31126121 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dairy foods (4–5 servings/day)
Number of subjects: 135
Study 31126121 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium + vitamin D supplements (1500 mg/day Ca and 600 IU/day vitamin D)
Number of subjects: 135
Study 31126121 — intervention group
Group type: COMPARATOR
Intervention: Placebo pills (Control)
Number of subjects: 135
Study 30209154 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot handover training curriculum (n=69)
Number of subjects: 147
Study 30209154 — intervention group
Group type: COMPARATOR
Intervention: Standard existing curriculum (n=78)
Number of subjects: 147
Study 26694929 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral-bupivacaine-dexmedetomidine (PBD)
Number of subjects: 45
Study 26694929 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral-bupivacaine (PB)
Number of subjects: 45
Study 26694929 — intervention group
Group type: COMPARATOR
Intervention: Control (C) - sham block with 2 ml normal saline
Number of subjects: 45
Study 24666144 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional therapy (focused on sleep and daily lifestyle regularity)
Number of subjects: 38
Study 24666144 — intervention group
Group type: COMPARATOR
Intervention: Control therapy (focused on emotional issues, avoiding sleep and lifestyle regularity)
Number of subjects: 38
Study 23031406 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First Ethno‐Racial Intensive Case Management (HF ER‐ICM)
Number of subjects: 100
Study 23031406 — intervention group
Group type: COMPARATOR
Intervention: Control group members
Number of subjects: 100
Study 20459717 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategy for external cephalic version (ECV)
Number of subjects: 100
Study 17889491 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral gemifloxacin
Number of subjects: 0
Study 17889491 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide
Number of subjects: 0
Study 15953714 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (EPO) 10000 IU thrice weekly subcutaneously (n = 211)
Number of subjects: 316
Study 15953714 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC) (n = 105)
Number of subjects: 316
Study 12756510 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 5 mg
Number of subjects: 48
Study 12756510 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 3.75 mg
Number of subjects: 48
Study 12756510 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam 1 mg
Number of subjects: 48
Study 12756510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 10368229 — intervention group
Group type: COMPARATOR
Intervention: Fraction II from control samples
Number of subjects: 40
Study 10368229 — intervention group
Group type: EXPERIMENTAL
Intervention: Fraction II from hyperoxaluric urine (stone formers)
Number of subjects: 40
Study 10368229 — intervention group
Group type: EXPERIMENTAL
Intervention: Fraction I from both groups (stone formers and controls)
Number of subjects: 40
Study 8697548 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 L Ringer's lactate (Group 1)
Number of subjects: 92
Study 8697548 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 L Ringer's lactate (Group 2)
Number of subjects: 92
Study 2003796 — intervention group
Group type: EXPERIMENTAL
Intervention: Scatter photocoagulation
Number of subjects: 116
Study 2003796 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 116
Study 6609700 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 20mg once daily
Number of subjects: 31
Study 6609700 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400mg three times a day
Number of subjects: 31
Study 30732654 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 994
Study 30732654 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilation (MV)
Number of subjects: 994
Study 30732654 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall discomfort score of the 18-item version of IPREA
Number of subjects: 994
Study 30732654 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 994
Study 29555497 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient physical therapy (PT) for 6 weeks
Number of subjects: 52
Study 29555497 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised home exercise program for 6 weeks
Number of subjects: 52
Study 28011813 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose MV
Number of subjects: 0
Study 28011813 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose MV with OPV0 in the first week of life
Number of subjects: 0
Study 28011813 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose MV with OPV0 after the first month of life
Number of subjects: 0
Study 28011813 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose MV without campaign-OPV
Number of subjects: 0
Study 28011813 — intervention group
Group type: COMPARATOR
Intervention: 1-dose MV with campaign-OPV before enrolment
Number of subjects: 0
Study 28011813 — intervention group
Group type: COMPARATOR
Intervention: 2-dose MV with campaign-OPV before enrolment
Number of subjects: 0
Study 24803100 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg simvastatin day(-1) with 75 mg clopidogrel day(-1)
Number of subjects: 13
Study 24803100 — intervention group
Group type: COMPARATOR
Intervention: 80 mg fluvastatin day(-1) with 75 mg clopidogrel day(-1)
Number of subjects: 13
Study 24803100 — intervention group
Group type: COMPARATOR
Intervention: 75 mg clopidogrel day(-1) alone
Number of subjects: 13
Study 24803100 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg clopidogrel day(-1) with simvastatin
Number of subjects: 13
Study 24803100 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg clopidogrel day(-1) with fluvastatin
Number of subjects: 13
Study 21914768 — intervention group
Group type: EXPERIMENTAL
Intervention: TC + TSE information group
Number of subjects: 443
Study 21914768 — intervention group
Group type: EXPERIMENTAL
Intervention: TC information group
Number of subjects: 443
Study 21914768 — intervention group
Group type: COMPARATOR
Intervention: No information control group
Number of subjects: 443
Study 19276396 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 80 mg/m2 with NVBiv 30 mg/m2 on day 1 and NVBo 80 mg/m2 on day 8 every 3 weeks (arm A)
Number of subjects: 390
Study 19276396 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 75 mg/m2 and DCT 75 mg/m2 on day 1 every 3 weeks (arm B)
Number of subjects: 390
Study 17178252 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotrafilcon A
Number of subjects: 20
Study 17178252 — intervention group
Group type: COMPARATOR
Intervention: Etafilcon A
Number of subjects: 20
Study 15219332 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco deprivation for 5 hours
Number of subjects: 78
Study 15219332 — intervention group
Group type: COMPARATOR
Intervention: Control (not deprived of tobacco)
Number of subjects: 78
Study 12150702 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine modulation strategies (blocking or attenuating TNF-alpha and IL-1beta activity)
Number of subjects: 0
Study 12150702 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental therapies involving IL-10, transforming growth factor-beta, granulocyte colony-stimulating factor, and IFN-phi
Number of subjects: 0
Study 12150702 — intervention group
Group type: EXPERIMENTAL
Intervention: Less known cytokines such as macrophage migration inhibitory factor and high mobility group 1 protein
Number of subjects: 0
Study 9638985 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of behenoyl‐cytosine‐arabinoside (BHAC), daunorubicin (DNR), 6‐mercaptopurine (6‐MP) and prednisolone (PSL)
Number of subjects: 59
Study 9638985 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual leukemic cell counts of less than 300 cells/microl in the bone marrow at the end point of induction therapy
Number of subjects: 59
Study 8074068 — intervention group
Group type: EXPERIMENTAL
Intervention: 42 g fat
Number of subjects: 8
Study 8074068 — intervention group
Group type: COMPARATOR
Intervention: 31 g fat
Number of subjects: 8
Study 2698940 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine
Number of subjects: 16
Study 2698940 — intervention group
Group type: EXPERIMENTAL
Intervention: lacidipine
Number of subjects: 16
Study 29980128 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient and day hospital treatment
Number of subjects: 518
Study 29980128 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresponse at the end of treatment
Number of subjects: 518
Study 28489240 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline injection into the tonsillar capsule during electrical tonsillectomy
Number of subjects: 0
Study 28489240 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injection during electrical tonsillectomy
Number of subjects: 0
Study 25589220 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg single dose
Number of subjects: 0
Study 25589220 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg single dose with ketoconazole 400 mg once daily
Number of subjects: 0
Study 25589220 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole 400 mg once daily
Number of subjects: 0
Study 25589220 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib in the presence of ketoconazole
Number of subjects: 0
Study 24267874 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved hand and respiratory hygiene measures
Number of subjects: 0
Study 24267874 — intervention group
Group type: COMPARATOR
Intervention: Control households (no intervention)
Number of subjects: 0
Study 24267874 — intervention group
Group type: EXPERIMENTAL
Intervention: Households with confirmed influenza A
Number of subjects: 0
Study 24267874 — intervention group
Group type: EXPERIMENTAL
Intervention: Households with confirmed influenza B
Number of subjects: 0
Study 21385289 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation ON
Number of subjects: 7
Study 21385289 — intervention group
Group type: COMPARATOR
Intervention: Sacral nerve stimulation OFF
Number of subjects: 7
Study 18460478 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan 4.5 g per day
Number of subjects: 65
Study 18460478 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan 6.75 g per day
Number of subjects: 65
Study 18460478 — intervention group
Group type: COMPARATOR
Intervention: Glucomannan 6.75 g per day
Number of subjects: 65
Study 18460478 — intervention group
Group type: COMPARATOR
Intervention: Control (0 g chitosan)
Number of subjects: 65
Study 16164527 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 0
Study 11818160 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of AVA 4 weeks apart IM
Number of subjects: 173
Study 11818160 — intervention group
Group type: EXPERIMENTAL
Intervention: IM administration of AVA
Number of subjects: 173
Study 11818160 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ administration of AVA
Number of subjects: 173
Study 11818160 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer dose interval between first two doses
Number of subjects: 173
Study 11818160 — intervention group
Group type: COMPARATOR
Intervention: Control group (licensed schedule and route)
Number of subjects: 173
Study 10223393 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive recall treatments at 3-month intervals
Number of subjects: 0
Study 10223393 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive recall treatments at 6-month intervals
Number of subjects: 0
Study 10223393 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive recall treatments at 12-month intervals
Number of subjects: 0
Study 10223393 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive recall treatments at 18-month intervals
Number of subjects: 0
Study 10223393 — intervention group
Group type: COMPARATOR
Intervention: Supportive recall treatments (all groups)
Number of subjects: 0
Study 7742152 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg tablet of 882C87
Number of subjects: 18
Study 7742152 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg i.v. of 882C87
Number of subjects: 18
Study 7742152 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of [14C]-882C87
Number of subjects: 18
Study 2038185 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of 1 liter of saline
Number of subjects: 0
Study 2038185 — intervention group
Group type: EXPERIMENTAL
Intervention: Donation of 1 unit of blood
Number of subjects: 0
Study 2038185 — intervention group
Group type: COMPARATOR
Intervention: Bed rest
Number of subjects: 0
Study 7046543 — intervention group
Group type: COMPARATOR
Intervention: Prednisone only (Group 1)
Number of subjects: 41
Study 7046543 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide and oral azathioprine (Group 2)
Number of subjects: 41
Study 7046543 — intervention group
Group type: EXPERIMENTAL
Intervention: Boluses of intravenous cyclophosphamide (Group 3)
Number of subjects: 41
Study 7046543 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 41
Study 7046543 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (Prednisone only)
Number of subjects: 41
Study 7046543 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups 2 and 3 (Cyclophosphamide and Azathioprine)
Number of subjects: 41
Study 31603998 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17β-estradiol patch (PATCH) with 200 mg cyclic oral micronized progesterone
Number of subjects: 75
Study 31603998 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 30 μg ethinyl estradiol and 0.15 mg desogestrel pill (PILL)
Number of subjects: 75
Study 31603998 — intervention group
Group type: COMPARATOR
Intervention: No estrogen/progesterone (NONE)
Number of subjects: 75
Study 31603998 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17β-estradiol patch (PATCH)
Number of subjects: 75
Study 31594740 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedative use
Number of subjects: 95
Study 31594740 — intervention group
Group type: EXPERIMENTAL
Intervention: Restraint use
Number of subjects: 95
Study 28082671 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine vascular neurologist assessment
Number of subjects: 174
Study 28082671 — intervention group
Group type: COMPARATOR
Intervention: Onboard vascular neurologist assessment
Number of subjects: 174
Study 26347107 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 2 weeks on and 1 week off (2/1 schedule)
Number of subjects: 74
Study 26347107 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib 4 weeks on and 2 weeks off (4/2 schedule)
Number of subjects: 74
Study 23318347 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical stimuli applied to three gait muscles of each leg
Number of subjects: 15
Study 23318347 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses to being supported on a pediatric treadmill
Number of subjects: 15
Study 23318347 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendon reflex (T-reflex), vibration-induced inhibition of T-reflex (VIM-T-reflex), and tonic vibration-induced reflex (VIR) assessments
Number of subjects: 15
Study 23318347 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayley Scale gross motor portion scores
Number of subjects: 15
Study 23318347 — intervention group
Group type: EXPERIMENTAL
Intervention: General functioning of Ia-proprioceptive pathways
Number of subjects: 15
Study 21517712 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Cognitive Behavioral Therapy (ICBT)
Number of subjects: 164
Study 21517712 — intervention group
Group type: COMPARATOR
Intervention: Twelve-Step Facilitation (TSF)
Number of subjects: 164
Study 19307441 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 98
Study 19307441 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation commencing at the lowest point of superficial venous reflux
Number of subjects: 98
Study 19307441 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser energy of >60 J/cm
Number of subjects: 98
Study 19307441 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer wavelength lasers
Number of subjects: 98
Study 17786707 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 Gy radiotherapy to bulky area
Number of subjects: 160
Study 17786707 — intervention group
Group type: COMPARATOR
Intervention: No further therapy (chemotherapy-only group)
Number of subjects: 160
Study 15206303 — intervention group
Group type: EXPERIMENTAL
Intervention: TermoSpot liquid-crystal temperature indicator
Number of subjects: 15
Study 9690541 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha, 3 x 10(6) IU three times weekly by subcutaneous injection for 36 months or until melanoma recurrence
Number of subjects: 113
Study 9690541 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha
Number of subjects: 113
Study 9690541 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTR)
Number of subjects: 113
Study 7654890 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg daily followed by no maintenance treatment (OM)
Number of subjects: 225
Study 7654890 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily plus cisapride 5 mg t.d.s. followed by cisapride 5 mg t.d.s. maintenance treatment (OMCIS)
Number of subjects: 225
Study 7654890 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 5 mg t.d.s. maintenance treatment
Number of subjects: 225
Study 7654890 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily plus cisapride 5 mg t.d.s. (OMCIS)
Number of subjects: 225
Study 3069765 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine (Ponderal Pacaps)
Number of subjects: 44
Study 3069765 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 44
Study 3069765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 30761813 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique-intense training intervention (six 55-min sessions with five side-foot kick exercises)
Number of subjects: 0
Study 30761813 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 28541882 — intervention group
Group type: EXPERIMENTAL
Intervention: Web app education (Group 1)
Number of subjects: 50
Study 28541882 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 50
Study 26148680 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 36
Study 26148680 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterols 2 g
Number of subjects: 36
Study 26148680 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Pravastatin 40 mg and Phytosterols 2 g)
Number of subjects: 36
Study 26148680 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy
Number of subjects: 36
Study 23177167 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid (40 mg triamcinolone)
Number of subjects: 32
Study 23177167 — intervention group
Group type: COMPARATOR
Intervention: NSAID (60 mg ketorolac)
Number of subjects: 32
Study 21817957 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV)
Number of subjects: 503
Study 21817957 — intervention group
Group type: COMPARATOR
Intervention: 7-valent pneumococcal conjugate vaccine (7vCRM)
Number of subjects: 503
Study 19428882 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRV vaccine
Number of subjects: 390
Study 19428882 — intervention group
Group type: COMPARATOR
Intervention: MMR and varicella vaccines (separate injections)
Number of subjects: 390
Study 17034446 — intervention group
Group type: EXPERIMENTAL
Intervention: Reimbursement for smoking cessation treatment (SCT) for 6 months
Number of subjects: 1266
Study 17034446 — intervention group
Group type: COMPARATOR
Intervention: No reimbursement or information
Number of subjects: 1266
Study 15504187 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% end‐tidal sevoflurane inhalation
Number of subjects: 9
Study 15504187 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7% end‐tidal sevoflurane inhalation
Number of subjects: 9
Study 15504187 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0% end‐tidal sevoflurane inhalation
Number of subjects: 9